Study Evaluates Pembrolizumab Plus Lenvatinib for Advanced or Recurrent Uterine Carcinosarcoma
Uterine carcinosarcoma is responsible for more than 16% of all deaths caused by uterine malignancy, despite its rarity.
Advertisement

Latest News

Advertisement
Advertisement
Our Contributors

Expert Interviews

Conference Highlights

Sibylle Loibl, MD, PhDConferences | June 11, 2025
Dr. Loibl discusses the importance of involving nurses in breast cancer treatment to mitigate medication side effects.
View More
Laura LitwinGVHD | June 11, 2025
Chronic GVHD can increase the risk of infections, graft failure, and multi-organ dysfunction in patients.
Laura LitwinConferences | June 10, 2025
The open-label phase 2 clinical trial enrolled 33 patients with resectable, high-risk ccRCC.
Laura LitwinConferences | June 11, 2025
Optimal management of non-clear cell renal cell carcinoma remains an unmet need.

Network Websites